Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?
Cancers (Basel). 2019 Jun 17;11(6):834. doi: 10.3390/cancers11060834.ABSTRACTUveal…
Enhanced antitumor efficacy of an oncolytic adenovirus armed with an EGFR-targeted BiTE using menstrual blood-derived mesenchymal stem cells as carriers
Cancer Gene Ther. 2020 May;27(5):383-388. doi: 10.1038/s41417-019-0110-1.…
Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer
Cancers (Basel). 2019 Jun 13;11(6):817. doi: 10.3390/cancers11060817.ABSTRACTUveal…
New perspectives on screening and early detection of endometrial cancer
Int J Cancer. 2019 Dec 15;145(12):3194-3206. doi: 10.1002/ijc.32514.…
Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma
Oncologist. 2019 Oct;24(10):1375-1383. doi: 10.1634/theoncologist.2018-0718.…
Clinical predictors of survival in metastatic uveal melanoma
Jpn J Ophthalmol. 2019 Mar;63(2):197-209. doi: 10.1007/s10384-019-00656-9.…
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet Oncol. 2019 Mar;20(3):408-419. doi: 10.1016/S1470-2045(18)30860-X.…
Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager
J Immunother Cancer. 2019 Jan 25;7(1):19. doi: 10.1186/s40425-019-0505-4.ABSTRACTBACKGROUND:…
Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01
Sci Transl Med. 2019 Jan 23;11(476):eaat9321. doi: 10.1126/scitranslmed.aat9321.ABSTRACTRetinoblastoma…
PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer
J Clin Oncol. 2019 Feb 20;37(6):490-503. doi: 10.1200/JCO.18.00358.…
IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1
J Immunol. 2019 Feb 1;202(3):787-798. doi: 10.4049/jimmunol.1800717.…
Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients
Gynecol Oncol. 2019 Feb;152(2):270-277. doi: 10.1016/j.ygyno.2018.11.036.…
